collection
MENU ▼
Read by QxMD icon Read
search

Obinutuzumab

shared collection
16 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26314773/diffuse-large-b-cell-lymphoma-dlbcl-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#1
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh, M Ladetto
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26190254/obinutuzumab-in-hematologic-malignancies-lessons-learned-to-date
#2
REVIEW
Tim Illidge, Christian Klein, Laurie H Sehn, Andrew Davies, Gilles Salles, Guillaume Cartron
The routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the clinical success achieved with rituximab, relapses are still common with further improvements in anti-CD20 mAb efficacy required. Many novel anti-CD20 antibodies are in development, but obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing. Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death...
November 2015: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/26251607/new-developments-in-the-treatment-of-chronic-lymphocytic-leukemia-role-of-obinutuzumab
#3
REVIEW
Arpita Shah
Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent cellular cytotoxicity and direct cell death, leading to superior cytotoxicity compared with rituximab. The approval of obinutuzumab by US Food and Drug Administration was based on a pivotal, phase III, randomized trial of chlorambucil monotherapy (n=118), chlorambucil plus obinutuzumab (n=333), or chlorambucil plus rituximab (n=330) in previously untreated patients with CLL...
2015: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/25512118/a-network-meta-analysis-of-progression-free-survival-and-overall-survival-in-first-line-treatment-of-chronic-lymphocytic-leukemia
#4
REVIEW
Piotr Ladyzynski, Maria Molik, Piotr Foltynski
BACKGROUND: A limited evidence exists regarding comparisons of clinical effectiveness of available therapies for first-line treatment of chronic lymphocytic leukemia (CLL). METHODS: We compared available therapies for treatment-naïve, symptomatic CLL regarding progression free survival (PFS) and overall survival (OS) in all the identified random control trials and in subgroups composed of younger/fit and older/unfit patients, using a Bayesian network meta-analysis...
February 2015: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/25538980/obinutuzumab-gazyva-for-chronic-lymphocytic-leukemia
#5
(no author information available yet)
No abstract text is available yet for this article.
November 10, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/25586272/obinutuzumab-a-review-of-its-use-in-patients-with-chronic-lymphocytic-leukaemia
#6
REVIEW
Sheridan M Hoy
Obinutuzumab (Gazyva(®); Gazyvaro(®)) is an intravenously administered, glycoengineered, humanized, type II, anti-CD20 monoclonal antibody of the IgG1 subclass. It is available in the EU and the USA as combination therapy with oral chlorambucil in adults with previously untreated chronic lymphocytic leukaemia (CLL). In a multinational phase III study in this patient population, obinutuzumab plus chlorambucil significantly prolonged progression-free survival compared with oral chlorambucil alone and intravenous rituximab plus oral chlorambucil...
February 2015: Drugs
https://www.readbyqxmd.com/read/25634683/obinutuzumab-as-frontline-treatment-of-chronic-lymphocytic-leukemia-updated-results-of-the-cll11-study
#7
LETTER
V Goede, K Fischer, A Engelke, R Schlag, S Lepretre, L F C Montero, M Montillo, C Fegan, E Asikanius, K Humphrey, G Fingerle-Rowson, M Hallek
No abstract text is available yet for this article.
July 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/25664270/obinutuzumab-a-fda-approved-monoclonal-antibody-in-the-treatment-of-untreated-chronic-lymphocytic-leukemia
#8
Mamta Sachdeva, Sameer Dhingra
Chronic lymphocytic leukemia (CLL) is an adult lymphoid malignancy with a variable clinical course. There is considerable interest in the identification of new treatments, as most current approaches are not curative. While most patients respond to initial chemotherapy, relapsed disease is often resistant to the drugs commonly used in CLL and patients are left with limited therapeutic options. Obinutuzumab is recently approved in combination with chlorambucil for people with previously untreated CLL and is additionally being investigated in a large clinical program, including multiple head-to-head phase III studies compared with Rituxan in indolent non-Hodgkin's lymphoma and diffuse large B-cell lymphoma...
January 2015: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/25691812/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-of-obinutuzumab
#9
REVIEW
Lukáš Smolej
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/25733804/clinical-role-of-obinutuzumab-in-the-treatment-of-naive-patients-with-chronic-lymphocytic-leukemia
#10
REVIEW
Sonia Cerquozzi, Carolyn Owen
The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab...
2015: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/25769620/obinutuzumab-plus-fludarabine-cyclophosphamide-or-bendamustine-in-the-initial-therapy-of-cll-patients-the-phase-1b-galton-trial
#11
MULTICENTER STUDY
Jennifer R Brown, Susan O'Brien, C Daniel Kingsley, Herbert Eradat, John M Pagel, James Lymp, Jamie Hirata, Thomas J Kipps
Obinutuzumab is a type 2, glycoengineered, anti-CD20 antibody recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL). In this nonrandomized, parallel-cohort, phase 1b, multicenter study, we explored the safety and preliminary efficacy of obinutuzumab-bendamustine (G-B) or obinutuzumab fludarabine cyclophosphamide (G-FC) for the therapy of previously untreated fit patients with CLL. Patients received up to 6 cycles of G-B (n = 20) or G-FC (n = 21). The primary end point was safety, with infusion-related reactions (88%, grade 3-4 20%) being the most common adverse event and grade 3-4 neutropenia in 55% on G-B and 48% on G-FC...
April 30, 2015: Blood
https://www.readbyqxmd.com/read/25817936/three-newly-approved-drugs-for-chronic-lymphocytic-leukemia-incorporating-ibrutinib-idelalisib-and-obinutuzumab-into-clinical-practice
#12
REVIEW
David S Sanford, William G Wierda, Jan A Burger, Michael J Keating, Susan M O'Brien
Three agents have received Food and Drug Administration (FDA) approval for treatment of chronic lymphocytic leukemia (CLL) within the past year. Ibrutinib and idelalisib block B-cell receptor signaling through inhibition of Bruton tyrosine kinase and phosphatidylinositol 3-kinase δ molecules respectively, interfering with several pathways required for leukemia cell survival. Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab. Ibrutinib has been studied in patients with relapsed CLL and as frontline therapy...
July 2015: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/25877943/obinutuzumab-ga101-for-the-treatment-of-chronic-lymphocytic-leukemia-and-other-b-cell-non-hodgkin-s-lymphomas-a-glycoengineered-type-ii-cd20-antibody
#13
REVIEW
Valentin Goede, Christian Klein, Stephan Stilgenbauer
Obinutuzumab (GA101) is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the FcγRIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. Preclinical data demonstrated more efficient B-cell depletion in whole blood and superior antitumor activity in xenograft models of obinutuzumab as compared to the type I CD20 antibody rituximab...
2015: Oncology Research and Treatment
https://www.readbyqxmd.com/read/25908509/chronic-lymphocytic-leukemia-2015-update-on-diagnosis-risk-stratification-and-treatment
#14
REVIEW
Michael Hallek
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen as well as B-cell markers...
May 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/25987688/role-of-obinutuzumab-in-the-treatment-of-chronic-lymphocytic-leukemia
#15
REVIEW
Gary W Jean, Jill M Comeau
PURPOSE: The pharmacology, pharmacokinetics, safety and efficacy, and place in therapy of obinutuzumab in the treatment of chronic lymphocytic leukemia (CLL) are reviewed. SUMMARY: Obinutuzumab, a fully humanized monoclonal antibody that targets the CD20 receptor on mature B cells, was recently approved for use in combination with chlorambucil in patients with previously untreated CLL. In a Phase III clinical trial including 671 patients with CLL and significant comorbidities, patients who received obinutuzumab-chlorambucil combination therapy had longer median progression-free survival than those who received rituximab plus chlorambucil (26...
June 1, 2015: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/26109852/obinutuzumab-treatment-in-the-elderly-patient-with-chronic-lymphocytic-leukemia
#16
REVIEW
Karen Seiter, Aleksandra Mamorska-Dyga
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Fludarabine-based regimens demonstrate higher response rates in younger patients but have a significant risk of infection and are thus poorly tolerated by older, frail patients. Anti-CD20 monoclonal antibodies have added to the efficacy of chemotherapy in CLL. Obinutuzumab is a potent Type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular toxicity and direct cell death compared with rituximab...
2015: Clinical Interventions in Aging
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"